The relatively low success rate of phase II oncology trials in predicting success of novel drugs in phase III trials and in gaining regulatory approval may be due to reliance on the endpoint of response rate defined by the Response Evaluation Criteria in Solid Tumors (RECIST). The neoadjuvant treatment paradigm allows the anti-tumor activity of a novel therapy to be determined on a pathological basis at the time of surgery instead of by RECIST, which was not developed to guide clinical decision making or correlate with long-term outcomes. Indeed, the US Food and Drug Administration (FDA) endorsed pathological complete response (pCR) as a surrogate for overall survival in early-stage breast cancer and granted accelerated approval to pertuzumab based on this endpoint. We propose that pathological response is a biologically rational method of determining treatment effect that may be more likely to predict overall survival. We discuss some advantages of the neoadjuvant trial design, review the use of neoadjuvant therapy as standards of care, and consider the neoadjuvant platform as a method for drug development.
Introduction
The primary objective of phase II trials in oncology has been to determine whether a novel drug has sufficient antitumor activity to warrant further investigation in phase III trials. Because of the cost and number of patients required, the failure of a phase III trial has detrimental financial and human ramifications. Most observers have concluded that phase II studies in oncology have had a poor track record in predicting success in phase III trials as well as eventual regulatory approval (1) . By one estimate, only 57% of oncology drugs taken from phase II to phase III obtain US Food and Drug Administration (FDA) approval, a proportion notably lower than for non-oncology drugs (2) . The likelihood that a positive phase II trial of combination therapy will result in a subsequent trial that improves the standard of care within 5 years has been reported to be only 0.038 (3).
This low predictive value of phase II trials may be due to reliance on the endpoint of response rate (RR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) (2) . RECIST was based on work done decades ago to standardize tumor responses in the absence of modern cross-sectional imaging techniques (4, 5) . Criteria for partial responses were based on the precision with which oncologists could differentiate solid spheres of different sizes under a layer of foam rubber (4) , not based on clinical outcomes. There was never any claim that the partial response criteria correlated with clinically meaningful outcomes. In fact, the original WHO response criteria (5) and later RECIST (6) stressed that "it is not intended that these RECIST guidelines play a role in…decision making, except if determined appropriate by the treating oncologist" (6) . Therefore, it is not surprising that RR has not been a reliable endpoint for phase II trials (7-9).
It seems reasonable to speculate that pathological complete response (pCR) might correlate more strongly with overall survival (OS) than response rates defined by RECIST. pCR is a biologically rational reflection of a therapy's ability to eradicate metastatic disease and may therefore serve as a surrogate for OS. Since the number of tumor cells in undetectable micrometastases is many logs lower than the cell number in clinically evident tumors, even pathological responses less than complete eradication of the detectable tumor might correlate with improved overall survival. The strategy of neoadjuvant therapy (treatment prior to complete surgical resection) permits investigators to assess tumor response on a pathological basis. In this setting, it may be possible to assess treatment benefit in a more meaningful way than in traditional phase II trials using RECIST. In this review, we will consider the use of neoadjuvant trials as a way to identify treatments perhaps more likely to improve overall survival and as a strategy for drug development.
Correlation of Pathological Response and Overall Survival
Different measurements of pathological response after neoadjuvant therapy have been demonstrated to correlate with overall survival across various solid tumors (Table cancer studies and the relationship between pCR and long-term benefit was not always clear. To address these challenges, the FDA performed a pooled analysis of nearly 13,000 patients enrolled in neoadjuvant breast cancer trials (16) . The eradication of invasive cancer in both the resected breast tissue and regional lymph nodes was found to correlate more strongly with improved long-term outcomes than was tumor eradication in the breast alone. In addition, the pooled analysis found individual patients who attain a pCR had a 64% reduction in the risk of death compared with patients who did not. At the individual trial level, there was only a weak association between increases in the proportion of patients achieving a pCR and the ability of treatment to improve OS. However, the heterogeneous patient populations, the low overall rates of pCR, and the lack of targeted therapy in the trials included in the analysis can explain this finding (17) . Although the FDA ultimately concluded that pCR meets the surrogate endpoint criteria of being "reasonably likely to predict clinical benefit" (18), future pooled analyses of targeted therapy trials in biomarker defined breast cancer subtypes could help more firmly establish pCR as a surrogate endpoint for long-term outcomes (19).
In neoadjuvant bladder cancer trials, pathological response less than complete responses have been associated with improved overall survival (20) . In an analysis of 147 patients by Splinter et al., patients with muscle-invasive bladder cancer (MIBC) whose disease was downstaged to no muscle invasion (<pT2) after neoadjuvant chemotherapy experienced a 75% survival at 5-years compared to 20% survival for those whose tumors that still showed muscle-invasion (>pT2 residual disease) (21). The equivalency of pCR and <pT2 in predicting overall survival after neoadjuvant chemotherapy for bladder cancer was confirmed in a prospective trial (22) Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is a standard of care for muscle-invasive bladder cancer (MIBC). Randomized neoadjuvant trials using MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) (20) or CMV (cisplatin, methotrexate, and vinblastine) (39) prior to radical cystectomy have both been shown to improve survival compared to cystectomy alone. Patients receiving neoadjuvant MVAC had superior disease specific survival (HR=1.66, 95% CI, 1.22-2.45, p=0.002) and a trend toward superior overall survival (HR=1.33, 95% CI, 1.00-1.76) compared with patients who were managed with surgery alone, with an overall survival of 57% and 43% at 5 years, respectively (p=0.06). The neoadjuvant CMV trial reported that neoadjuvant CMV was associated with a 16% relative improvement in survival (p=0.037) and a 23% relative improvement in metastasis-free survival (p=0.0001) at 10 years. Given that gemcitabine and cisplatin (GC) is better tolerated and achieves similar survival rates to MVAC in the metastatic disease setting (40), it is frequently used as a substitute for MVAC in the neoadjuvant setting and has similar pathological response rates (41) . In a meta-analysis of over 3,000 patients with MIBC, there was a 5-year overall survival benefit seen with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy versus radical cystectomy alone (HR=0.86, 95% CI, 0.77-0.95, p=0.003) (33).
Non-small cell lung cancer (NSCLC)
In patients with resectable NSCLCs, neoadjuvant chemotherapy can improve overall survival. In the 1990's, two small, randomized trials were terminated early on the basis of an interim analysis showing significant improvement in survival for neoadjuvant chemotherapy followed by surgery versus surgery alone (42, 43) . In a meta-analysis of Although an improvement in pCR ultimately led to the accelerated approval of pertuzumab, the other factors that were crucial to the FDA decision reveal important, generalizable considerations for using neoadjuvant therapy as a platform for drug development ( Figure 1) . First, patients with HER2-positive breast cancer are at high risk for relapse with standard therapy (15) . Second, the safety profile of pertuzumab alone and in combination with standard of care chemotherapy and trastuzumab had been reported in nearly 10,000 patients (17) . Third, the FDA had conducted the aforementioned pooled analysis of neoadjuvant trials to establish the definition of pCR and to support the relationship between pCR and overall survival at the patient level (16) . Lastly, the adjuvant APHINITY confirmatory trial was fully accrued and well underway at the time of accelerated approval, complying with the FDA requirement for a post-marketing clinical trial to verify meaningful clinical benefit (50).
The bar for the first approval of a drug based on pathological response was set high but has provided an impetus to pursue this pathway of expedited drug 
